Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | CPT1A | P50416 | 11/20 | 0.57 |
| ▸ | CPT1B | Q92523 | 10/20 | 0.57 |
| ▸ | CPT2 | P23786 | 8/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570410 | 0.90 | MAPT (0.54) | MAPTCPT1ACPT1BCPT2SMN1; SMN2 | |
| SCHEMBL3580790 | 0.89 | CPT1A (0.60) | MAPTCPT1ACPT1BCPT2 | |
| SCHEMBL3579488 | 0.89 | CPT1A (0.68) | MAPTCPT1ACPT1BCPT2SMN1; SMN2 | |
| SCHEMBL30015611 | 0.89 | CPT1A (0.68) | MAPTCPT1ACPT1BCPT2SMN1; SMN2 | |
| SCHEMBL3573751 | 0.88 | CPT1A (0.74) | MAPTCPT1ACPT1BCPT2 | |
| SCHEMBL3576685 | 0.85 | CPT1A (0.61) | MAPTCPT1ACPT1BCPT2SMN1; SMN2 | |
| SCHEMBL3569709 | 0.84 | CPT1A (0.66) | MAPTCPT1ACPT1BCPT2SMN1; SMN2 | |
| SCHEMBL3577008 | 0.83 | CPT1A (0.82) | MAPTCPT1ACPT1BCPT2 | |
| SCHEMBL3571493 | 0.83 | CPT1A (0.70) | MAPTCPT1ACPT1BCPT2 | |
| SCHEMBL30016507 | 0.83 | CPT1A (0.70) | MAPTCPT1ACPT1BCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | MAPT 1807/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.